🔗 Share this article

While the United States undertakes historic revisions to its vaccination schedules, one figure has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the pandemic and has zeroed in on alleged deaths following Covid vaccination in her brief position at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Schedule

Public health authorities were set to unveil major changes to the childhood immunization program in December, bringing the US with Denmark’s national calendar, sources say – a major change that would place the US at odds with much of the world with little proof for benefit. The announcement has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to speak at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

A Shift at the FDA

This interim role may indicate a closer partnership between the drug and vaccine centers as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood vaccine recommendations in the US in order to be more similar to the Danish model, a society with nationalized medicine and a population approximately the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has little discernible track record in drug development, regulation or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She appears not to have any of the qualifications” for leading the CDER, said Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a large organization. She lacks background in drug approvals.”

Previous directors of CBER would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that prior appointees who headed the center have had.”

This division has an immense range of responsibilities at the FDA, the former commissioner stated.

“The public just pays attention on the novel medication approvals, but the off-patent medication office approves numerous generic drugs. There is also a biosimilars division, OTC medication office and so forth, and each of these must be managed,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a significant administrative component to the role, which manages in excess of 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” Woodcock said.

Response and Disputed Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection indicates increased cooperation among FDA leaders on vaccines, a press secretary responded that the “concerns are based on incorrect premises”.

“This background matches the functions of her position,” the spokesperson said, pointing to the time Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a controversial one-day therapy clearance system that reportedly worried her former heads. “How are these therapies being picked for this fast-track system? Who takes the calls?” Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed regulations of all drugs, with the exception of immunizations.”

Established History on Vaccines

Concerning immunizations, Høeg has a clearer, if problematic, past, critics have noted. She published a study using unverified public submissions to determine the rate of myocarditis after Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed changing regulations for novel immunizations and ending “optional” vaccines, she stated after the election on a online show. At the FDA, Dr. Høeg has according to sources suggested preventing teenage boys from getting Covid vaccinations.

“She’s an thorough ideologue who begins with her beliefs and reverse-engineers to accommodate the data in a very misleading, untruthful way,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|